Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics has announced a presentation by its senior management team at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 2:15 p.m. ET. This event will feature a live webcast accessible via the company’s website, with a replay available for two weeks post-event.

The significance of this presentation lies in CRISPR Therapeutics’ pivotal role in the advancement of gene-based therapies, particularly with the approval of CASGEVY® (exa-cel), the first CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia. This milestone not only underscores the therapeutic potential of CRISPR technology but also highlights the company’s commitment to addressing a range of serious human diseases through its expanding pipeline, which includes applications in hemoglobinopathies, cardiovascular diseases, autoimmune disorders, oncology, and regenerative medicine. The introduction of the SyNTase™ editing platform further positions CRISPR Therapeutics at the forefront of gene editing, promising enhanced precision and scalability in gene correction.

The takeaway from this development is the potential shift in research paradigms within the longevity and healthspan fields. The successful application of CRISPR technology in treating genetic disorders may accelerate the exploration of gene editing as a viable strategy for age-related diseases. As CRISPR Therapeutics continues to forge strategic collaborations with biopharmaceutical partners, it may catalyze advancements in drug development timelines, ultimately leading to more rapid translation of gene therapies from bench to bedside. This could open new avenues for therapeutic interventions aimed at extending healthspan and improving quality of life in aging populations.

Source: globenewswire.com